Share Name Share Symbol Market Type Share ISIN Share Description
Cello Group LSE:CLL London Ordinary Share GB00B0310763 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 100.50p 99.00p 102.00p - - - 0.00 05:00:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Media 157.3 4.8 3.5 28.4 87.24

Cello (CLL) Latest News

More Cello News
Cello Takeover Rumours

Cello (CLL) Share Charts

1 Year Cello Chart

1 Year Cello Chart

1 Month Cello Chart

1 Month Cello Chart

Intraday Cello Chart

Intraday Cello Chart

Cello (CLL) Discussions and Chat

Cello Forums and Chat

Date Time Title Posts
04/1/201708:08Cello - solid prospects962.00
29/1/201516:56CELLO GROUP?9.00
12/1/200516:17Cello or EQI?-

Add a New Thread

Cello (CLL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
16/01/2017 15:57:35101.407,0007,098.00O
16/01/2017 14:20:0599.781,3721,368.98O
16/01/2017 13:49:4299.781,3721,368.98O
16/01/2017 08:06:54102.003,4843,553.68O
View all Cello trades in real-time

Cello (CLL) Top Chat Posts

Cello Daily Update: Cello Group is listed in the Media sector of the London Stock Exchange with ticker CLL. The last closing price for Cello was 100.50p.
Cello Group has a 4 week average price of 102.38p and a 12 week average price of 100.58p.
The 1 year high share price is 114p while the 1 year low share price is currently 78p.
There are currently 86,809,162 shares in issue and the average daily traded volume is 64,717 shares. The market capitalisation of Cello Group is £87,243,207.81.
davebowler: Finncap; Price: 106.0p Target Price: 132p Cello has an overlooked and potentially significantly undervalued asset that is now out of development phase. Cello Pulsar is a social media analytics tool that has significant points of difference to the competition. In the right hands, social media data can inform, direct and optimise marketing campaigns but to date its usage has been constrained by early-stage science and customer unfamiliarity. Competitors in this area have individually raised nearly half of Cello's market cap, emphasising Pulsar’s potential to add very material value to the share price. We initiate at Buy.
qs9: nice IMO to see directors taking advantage of recent share price weakness...
hpcg: I think its a bit chicken and egg with regards to liquidity / spread; its thinly traded which puts people off. If they participated then there would be more liquidity! However I'm speculating as to the motives of others, and it could just be that investors want to see more prolonged evidence of progress. If the company does the business the share price will as well.
stegrego: Hybridan Cello Group (CLL 46p/£28.25m) Cello continues its impressive share price performance with a further rise of over 25 per cent since the end of July when we last commented on the Company. Today it announced its half year results showing headline ongoing operating profit up 25 per cent to £3.3m (2009: £2.6m), margins improved to 10.9 per cent (2009: 8.9 per cent) and net debt down to £11.7m (2009: £14.8m). The fall off in income from the public sector has not impacted materially the overall mix of business, with the top 20 clients from 2009 remaining significant revenue generators for the Company in 2010, with many increasing their levels of expenditure. The largest customer accounts for only 4.4 per cent of total income, with the top 20 customers for less than 40 per cent. The robust Pharmaceutical sector on the other hand now accounts for over 25 percent of the group's income. The Company thus appears to have created a secure and solid base from which to advance. On the results the CEO commented "We are now seeing a pick up from our clients in the private sector across a range of industries....(and) have started to carefully organically expand the business again". This positive statement, along with the small 5 percent increase in the interim dividend bodes well for investors who we expect to continue to support the progress of this growing company.
jeff h: Singer Capital Markets is initiating coverage of market research and consulting group Cello with a positive recommendation, saying that most of the company's earn out obligations from previous takeovers are behind it and the company is in a position again to expand through acquisition. The company's recent interim results demonstrated a return to positive growth despite extreme near term headwinds in the public sector, which Singer rates as "an exceptionally strong performance in this context." The broker thinks there are three main reasons to buy the shares. First is the aforementioned revenue growth. "Acquisitions are back on the agenda and will enhance growth. Cello's biggest business segment, Healthcare, is driving growth and international expansion offsetting the short term public sector headwind," the broker said. Cello chief executive Mark Scott told Sharecast earlier this week that the company "will buy again, probably in America" and that the plan is to double the size of Cello in the next two or three years. The second reason to buy cited by Singer is the company's strong positions in market research and healthcare. These are "scarce assets in a consolidating market." The broker also believes the shares are undervalued because the earnings are in the low part of the cycle. Compared to the valuation of its peers, the stock is cheap, and Singer thinks it is also undervalued on a sum of the parts (SOTP) basis and as a prospective takeover target. The stock trades on 6.6 times projected earnings per share for 2010 while the ratio of enterprise value to earnings before interest, tax, depreciation and amortisation is just 4.6. "This is clearly low," the broker argues. "If the share price does not recover then it is possible that Cello could become a target, given the scarcity value of its two operating units. We use a blended SOTP and peer based valuation to derive our 12 month target price, which we set at 71p, indicating over 50% upside," the broker concluded
maksud: undervalued. suprise no uplift in share price.
jeff h: The reason this one being bought is the IC reckon the directors cheesed off with the low share price and may launch a MBO unless it's re-rated.
glasshalfull: Signs of life in the CLL share price in the last few sessions. If recent years are anything to go by then there is a very strong chance of a trading update anytime now. Trading statements released on the following dates:- 3rd July 2009 4th July 2008 12th July 2007 3rd July 2006 2010 market updates 19th January 2010 - pre-close trading update indicated that there were signs of improvement in markets. 16th March 2010 preliminary results confirmed improvement, "Cello has strong revenue pipelines in Research and Consulting and Tangible has also seen a marked increase in levels of new business activity." 17th May 2010 - AGM statement noted "The Group has therefore performed strongly during the first quarter of 2010. While there remains economic uncertainty, we are growing in confidence about the Group's performance." So, given that guidance in 2010 has been of improving markets and strong performance (so far) I'm hopeful that CLL will be in line with market forecasts at the very least....and there's always a possibility that they may be ahead. Worth reiterating m my earlier post - 364 Altium snippet on AGM update "...we continue to view the group's stock as substantially undervalued and would cite: (a) the quality of its underlying operating assets, (b) robust financials (debt well within long-term facilities of £17m), and (c) earnings growth potential as a recovery in research and marketing spend plays through a scaleable cost base, as key attractions. We are nudging up our target price from 46p to 49p (an undemanding 7x FY 2010E PER / c.48% upside) to reflect the encouraging momentum highlighted above and reiterate our BUY recommendation." Regards, GHF
glasshalfull: I agree re. Chime. It looks good value. As for Cello, 46% of research revenues derive from abroad with MD recently appointed to drive growth in the US. I'm hoping that Next Fifteens comment re. strong recovery in its US business will therefore spill over to Cello. The market has been (understandbly) concerned with CLL's earnout obligations and increasing debt levels while they were also hit with the double whammy of issuing shares as part of earnout obligations way below the price that would have been anticipated a few years back. As a consequence they have suffered disproportionate dilution to a degree given that they were not in a position to settle purely in cash. However, the 2nd half of 2009 indicates that the markets worries are unfounded. Net debt was £14.8 million at the interim stage and this had reduced further to £11.5 million at year end. Earnouts are down to £6.1m which will be spread over the next 3 years. Given their strong cash generation, £4.3 million of costs stripped from the business and prospects improving - especially research which accounts for 60% of the business at margins that have held up well in the mid teens - then I'm hoping that an AGM statement confirming the improvements will result in CLL coming off market lows in terms of share price and enjoying a re-rating which many of their peers have experienced over the last 6 months or so. Regards, GHF
glasshalfull: Well I disagree GCI :-) I've been nibbling away and have bought a few CLL since results which I expect to represent the nadir of the share price underperformance. I had researched and was a holder of CLL back in 2006 and discovered that I still had a few (dormant account), so only recently got up to speed on developments since. My interest was rekindled having carried out comprehensive research on Adventis (ATG) a marketing services company - see link below - and I noticed that both ATG and CLL had failed to enjoy the shareprice recovery that many of their peers had. I've started a write-up on CLL and will post when complete. Regards GHF
Cello share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20170117 07:02:20